IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 19.51

Change

+0.38 (+1.99)%

Market Cap

USD 0.10B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-15 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.63 (+2.02%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+1.20 (+1.94%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+1.45 (+1.43%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+1.40 (+1.70%)

USD 0.16B
XHS SPDR® S&P Health Care Service..

+2.10 (+2.13%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.64 (+2.31%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.47 (+1.75%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+1.24 (+2.29%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.25 (+1.43%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

+1.31 (+2.80%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.79% 19% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.79% 19% F 13% F
Trailing 12 Months  
Capital Gain -19.61% 14% F 15% F
Dividend Return 0.46% 44% F 6% D-
Total Return -19.16% 14% F 14% F
Trailing 5 Years  
Capital Gain -44.86% 10% F 9% A-
Dividend Return 2.59% 53% F 5% F
Total Return -42.28% 10% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -10.80% 5% F 6% D-
Dividend Return -10.22% 5% F 6% D-
Total Return 0.57% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 24.58% 10% F 40% F
Risk Adjusted Return -41.59% 5% F 7% C-
Market Capitalization 0.10B 60% D- 27% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.